MedTrace Logo

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

NCT04970043 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2021-07-21

No results posted yet for this study

Summary

A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness of cell lung cancer patients

Conditions

  • Lung Cancer Stage II

Interventions

DRUG

Camrelizumab+ pemetrexed + platinum

Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle. Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed. Maintenance treatment period: Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle. Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years).

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • lin Lin, doctor · Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2024-07-30
Completion
2024-07-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04970043 on ClinicalTrials.gov